Literature DB >> 17379411

Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses.

Richard Torres1, Susan D Croll, Jeffrey Vercollone, Joel Reinhardt, Jennifer Griffiths, Stephanie Zabski, Keith D Anderson, Niels C Adams, Lori Gowen, Mark W Sleeman, David M Valenzuela, Stanley J Wiegand, George D Yancopoulos, Andrew J Murphy.   

Abstract

Neuromedin U (NMU) has recently been reported to have a role in nociception and inflammation. To clarify the function of the two known NMU receptors, NMU receptor 1 (NMUR1) and NMU receptor 2 (NMUR2), during nociception and inflammation in vivo, we generated mice in which the genes for each receptor were independently deleted. Compared to wild type littermates, mice deficient in NMUR2 showed a reduced thermal nociceptive response in the hot plate, but not in the tail flick, test. In addition, the NMUR2 mutant mice showed a reduced behavioral response and a marked reduction in thermal hyperalgesia following capsaicin injection. NMUR2-deficient mice also showed an impaired pain response during the chronic, but not acute, phase of the formalin test. In contrast, NMUR1-deficient mice did not show any nociceptive differences compared to their wild type littermates in any of the behavioral tests used. We observed the same magnitude of inflammation in both lines of NMU receptor mutant mice compared to their wild type littermates after injection with complete Freund's adjuvant (CFA), suggesting no requirement for either receptor in this response. Thus, the pro-nociceptive effects of NMU in mice appear to be mediated through NMUR2, not NMUR1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379411     DOI: 10.1016/j.pain.2007.01.036

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  17 in total

Review 1.  Role of G protein-coupled receptors in inflammation.

Authors:  Lei Sun; Richard D Ye
Journal:  Acta Pharmacol Sin       Date:  2012-02-27       Impact factor: 6.150

Review 2.  In search of analgesia: emerging roles of GPCRs in pain.

Authors:  Laura S Stone; Derek C Molliver
Journal:  Mol Interv       Date:  2009-10

3.  Common variants at 5q33.1 predispose to migraine in African-American children.

Authors:  Xiao Chang; Renata Pellegrino; James Garifallou; Michael March; James Snyder; Frank Mentch; Jin Li; Cuiping Hou; Yichuan Liu; Patrick M A Sleiman; Hakon Hakonarson
Journal:  J Med Genet       Date:  2018-09-28       Impact factor: 6.318

Review 4.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Authors:  J D Mitchell; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

5.  Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping.

Authors:  Meiping Chang; Sarah Smith; Andrew Thorpe; Michael J Barratt; Farzana Karim
Journal:  Mol Pain       Date:  2010-09-16       Impact factor: 3.395

6.  Diet-induced obesity differentially regulates behavioral, biomechanical, and molecular risk factors for osteoarthritis in mice.

Authors:  Timothy M Griffin; Beverley Fermor; Janet L Huebner; Virginia B Kraus; Ramona M Rodriguiz; William C Wetsel; Li Cao; Lori A Setton; Farshid Guilak
Journal:  Arthritis Res Ther       Date:  2010-07-06       Impact factor: 5.156

7.  The neuropeptide neuromedin U promotes autoantibody-mediated arthritis.

Authors:  Sindhuja M Rao; Jennifer L Auger; Philippe Gaillard; Ralph Weissleder; Etsuko Wada; Richard Torres; Masayasu Kojima; Christophe Benoist; Diane Mathis; Bryce A Binstadt
Journal:  Arthritis Res Ther       Date:  2012-02-07       Impact factor: 5.156

8.  Appetite-modifying actions of pro-neuromedin U-derived peptides.

Authors:  David A Bechtold; Tina R Ivanov; Simon M Luckman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-16       Impact factor: 4.310

Review 9.  Neuromedin U: potential roles in immunity and inflammation.

Authors:  Yuan Ye; Zongan Liang; Luzheng Xue
Journal:  Immunology       Date:  2020-09-16       Impact factor: 7.397

Review 10.  Targeting spinal neuropeptide Y1 receptor-expressing interneurons to alleviate chronic pain and itch.

Authors:  Tyler S Nelson; Bradley K Taylor
Journal:  Prog Neurobiol       Date:  2020-08-07       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.